Results 71 to 80 of about 5,114,489 (264)

Lifestyle Management in Menopause: A Systematic Review of Women With Premature Ovarian Insufficiency

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Premature ovarian insufficiency (POI), the loss of ovarian function before age 40, increases the risk of cardiovascular disease, low bone mineral density, dementia and psychological distress. Lifestyle interventions reduce chronic disease risk in other populations and, with hormone therapy, may improve health outcomes in POI.
Ladan Yeganeh, Nathalie Vermeulen, Carolyn Ee, Helena Teede, Amanda J. Vincent   +4 more
wiley   +1 more source

Acute unilateral anterior uveitis following zoledronic acid infusion: A case report

SAGE Open Medical Case Reports, 2020
Bisphosphonates are widely used to treat several clinical conditions. Zoledronic acid is one of this class, commonly used for the treatment and prevention of osteoporosis, hypercalcemia of malignancy, Paget’s disease, and multiple myeloma.
Kiruththihan Anandasayanan, Muthusamy Malaravan, Navaneethakrishnan Suganthan   +2 more
doaj   +1 more source

Influence of Zoledronic Acid on Atrial Electrophysiological Parameters and Electrocardiographic Measurements [PDF]

, 2015
INTRODUCTION: Our objective was to determine effects of zoledronic acid (ZA) on atrial electrophysiological parameters and electrocardiographic measurements.
Allen, Matthew R., Jaynes, Heather A., Kovacs, Richard J., Overholser, Brian R., Tisdale, James E.   +4 more
core   +1 more source

Soluble Sema4D From γδ T Cells Exerts Osteoblast Inhibition via Plexin‐B/mTOR Signalling Contributing to Pathogenesis of Bisphosphonate‐Related Osteonecrosis of the Jaws

Cell Proliferation, EarlyView.
Schematic summarizing the pathway of sSema4D from γδ T cells inhibiting osteoblast differentiation in BRONJ. ABSTRACT Bisphosphonate‐related osteonecrosis of the jaw (BRONJ) is a severe complication in patients undergoing long‐term bisphosphonate therapy, while our knowledge on the pathogenesis of BRONJ is far from sufficient.
Lingling Ou, Shijia Qiao, Zhuoyi Liao, Xiner Tan, Hui Huang, Zhiyan Zhou, Ruhui Luo, Weijun Zeng, Yan Yang, Zhongxuan Zhang, Jingchen Chen, Shengli Wang, Yiqin Jiang, Jianlei Hao, Yuqin Shen, Longquan Shao   +15 more
wiley   +1 more source

Lessons learned from long-term side effects after zoledronic acid infusion following denosumab treatment: a case report and review of the literature

Journal of Medical Case Reports, 2022
Background Zoledronic acid is an intravenous, highly potent aminobisphosphonate for use in patients with primary or secondary osteoporosis. Zoledronic acid-induced prolonged side-effects are well known and quite common.
Ilona Nurmi-Lüthje, Peter Lüthje
doaj   +1 more source

Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT) [PDF]

, 2012
Measurements of change in bone mineral density (BMD) are thought to be weak predictors of treatment effect on the reduction of fracture risk. In this study we report an alternative year-on-year approach for the estimation of treatment effect explained by
Austin, Black, Black, Black, Bruyere, Bruyere, Cummings, Delmas, Eastell, Genant, Li, Lin, Marshall, Miller, Orwoll, Sarkar, Watts, Watts, Wickham   +18 more
core   +1 more source

Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study—Asian Subgroup Analysis

Advances in Therapy, 2020
Introduction The primary analysis of a global phase 3 study that evaluated the efficacy and safety of denosumab versus zoledronic acid for preventing skeletal-related events (SREs) in adults with newly diagnosed multiple myeloma (MM) indicated that ...
Shang‐Yi Huang, S. Yoon, K. Shimizu, W. Chng, Cheng-Shyong Chang, R. Wong, Seasea Gao, Yang Wang, Steve W. Gordon, A. Glennane, C. Min   +10 more
semanticscholar   +1 more source

Alterations of bone proteins in medication‐related osteonecrosis of the jaw

European Journal of Oral Sciences, Volume 133, Issue 2, April 2025.
Abstract Changes in the protein expression pattern of osteoblastic lineage cells from the alveolar bone (OLAB) during medication‐related osteonecrosis of the jaw (MRONJ) have rarely been investigated. This lack of information is partly because of the limited availability of healthy samples and the lack of human alveolar bone cell lines for research ...
Andrea Schubert, Phillipp Brockmeyer, Philipp Kauffmann, Jan Wiegel, Florian Lautenbacher, Nicolai Miosge, Boris Schminke   +6 more
wiley   +1 more source

Comprehensive evaluation of compound Kushen injection combined with zoledronic acid in treating bone metastasis cancer pain based on meta-analysis and decision tree model

Frontiers in Pain Research
ObjectiveTo evaluate the safety, efficacy, and cost-effectiveness of combining Compound Kushen Injection (CKI) with zoledronic acid in the treatment of bone metastasis-induced cancer pain in malignant tumors.MethodsA comprehensive search of Chinese and ...
Xi Zhao, Tianwei Meng, Kaiqiang Wang, Xi Yan, Yuqiang Liu, Xinghua Li   +5 more
doaj   +1 more source

Anti-tumour activity of bisphosphonates in preclinical models of breast cancer [PDF]

, 2010
There is increasing evidence of anti-tumour effects of bisphosphonates from pre-clinical studies, supporting a role for these drugs beyond their traditional use in treatment of cancer-induced bone disease.
A Sasaki, A Sasaki, AC Hirbe, AJ Roelofs, C Melani, C Walter, D Santini, D Santini, DW Dempster, ER van Beek, EY Lin, F Daubiné, G Facchini, G Morgan, G Rennert, G van der Pluijm, GR Mundy, GR Mundy, H Eidtmann, H Mönkkönen, H Neville-Webbe, HK Brown, HL Benford, HM Weiss, Ingunn Holen, J Dai, J Soltau, J Wood, J Yamada, JH Lin, JM Tuomela, K Thompson, M Coscia, M Gnant, M Michailidou, M Neudert, MC Winter, MJ Simon, P Clézardin, PA Newcomb, PD Ottewell, PD Ottewell, PD Ottewell, PD Ottewell, PD Ottewell, PI Croucher, PP Provenzano, R Aft, RD Leek, RE Coleman, Robert E Coleman, S Meraviglia, SB Coffelt, SP Luckman, T Bäuerle, T Chen, T Hiraga, T Hiraga, T Hiraga, T Powles, T Ziebart, TL Aghaloo, V Kunzmann, WC Duivenvoorden, X Tang   +64 more
core   +2 more sources